Literature DB >> 11069313

Nitric oxide mediates a therapeutic effect of nicotine in ulcerative colitis.

J T Green1, C Richardson, R W Marshall, J Rhodes, H C McKirdy, G A Thomas, G T Williams.   

Abstract

BACKGROUND: Ulcerative colitis is a condition of nonsmokers in which nicotine is of therapeutic benefit. AIMS: To examine the in vitro effect of nicotine on colonic smooth muscle activity and the role of nitric oxide (NO) as a mediator.
METHODS: Nicotine, 1-10 microM, was administered to strips of circular muscle from the distal sigmoid colon of 9 patients with active ulcerative colitis and 18 with colorectal cancer. The effect of electrical field stimulation (EFS) was examined before nicotine was added. Finally L-NAME, a NO synthetase inhibitor, was added before nicotine was administered again.
RESULTS: Muscle strips developed similar spontaneous resting tone. In response to EFS, ulcerative colitis tissue developed lower tensions than the controls. Nicotine significantly reduced the resting tone and peak tension after EFS, with a greater effect in controls. With L-NAME, peak tensions were increased more in ulcerative colitis than controls, and nicotine produced a much smaller reduction.
CONCLUSIONS: Nicotine reduces circular muscle activity, predominantly through the release of nitric oxide-this appears to be 'up-regulated' in active ulcerative colitis. These findings may explain some of the therapeutic benefit from nicotine (and smoking) in ulcerative colitis and may account for the colonic motor dysfunction in active disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069313     DOI: 10.1046/j.1365-2036.2000.00847.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

1.  A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors.

Authors:  Christopher Heeschen; Michael Weis; Alexandra Aicher; Stefanie Dimmeler; John P Cooke
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  (E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa.

Authors:  Tanja Spoettl; Christine Paetzel; Hans Herfarth; Merouane Bencherif; Juergen Schoelmerich; Roland Greinwald; Gregory J Gatto; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2006-05-20       Impact factor: 2.571

Review 3.  Smoking in inflammatory bowel diseases: good, bad or ugly?

Authors:  Peter Laszlo Lakatos; Tamas Szamosi; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

Review 4.  Ulcerative colitis in smokers, non-smokers and ex-smokers.

Authors:  Guillermo Bastida; Belén Beltrán
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

5.  Comparative study of enema retention and preference in ulcerative colitis.

Authors:  J R Ingram; J Rhodes; B K Evans; R G Newcombe; G A O Thomas
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

6.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

7.  Nicotine enemas for active Crohn's colitis: an open pilot study.

Authors:  J R Ingram; J Rhodes; B K Evans; G A O Thomas
Journal:  Gastroenterol Res Pract       Date:  2008       Impact factor: 2.260

8.  Increased urinary nitrite, a marker of nitric oxide, in active inflammatory bowel disease.

Authors:  M G Goggins; S A Shah; J Goh; A Cherukuri; D G Weir; D Kelleher; N Mahmud
Journal:  Mediators Inflamm       Date:  2001-04       Impact factor: 4.711

9.  Long-Term Follow-Up, Association between CARD15/NOD2 Polymorphisms, and Clinical Disease Behavior in Crohn's Disease Surgical Patients.

Authors:  Francesco Giudici; Tiziana Cavalli; Cristina Luceri; Edda Russo; Daniela Zambonin; Stefano Scaringi; Ferdinando Ficari; Marilena Fazi; Amedeo Amedei; Francesco Tonelli; Cecilia Malentacchi
Journal:  Mediators Inflamm       Date:  2021-02-24       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.